Release Date: July 31, 2024
Expiration Date: July 31, 2025
Activity Overview
Advances in the understanding and treatment of generalized myasthenia gravis (gMG) have marked significant progress in recent years. Strategies that address therapeutic targets, including inhibiting complement protein and FcRN have advanced disease management Moreover, advances in immunomodulatory therapies and symptomatic management strategies have improved outcomes and quality of life for many MG patients. These developments underscore the ongoing efforts to enhance treatment options and find effective solutions tailored to the diverse needs of individuals living with gMG. As research continues to expand our understanding of the underlying mechanisms of the disease, there is hope for even more innovative approaches on the horizon.
This online educational activity is designed to provide expert perspectives of newer and emerging data on the treatment of gMG, with a focus on complement inhibitors and FcRN inhibitors their real-world use in impact clinical practice. It uses a case-based approach to highlight the key messages shred by the expert faculty.
Target Audience
This educational activity is directed toward neurologists, specialty NPs and PAs, RNs, and other HCPs involved in the management of patients with gMG.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate emerging data on complement-targeted therapies for generalized myasthenia gravis
- Identify the role of newer complement-directed agents in the treatment of patients with generalized myasthenia gravis
- Design individualized management plans for patients with generalized myasthenia gravis
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
